Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers

IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC)

(2016) J. Bellmunt et al.   ANNALS OF ONCOLOGY

First evidence of significant clinical activity of PD-1 inhibitors in metastatic, castration resistant prostate cancer (mCRPC)

(2016) J.N. Graff et al.   ANNALS OF ONCOLOGY

Systematic review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy

(2016) P. Bossi et al.   ANNALS OF ONCOLOGY

Nivolumab-induced thyroid dysfunction

(2016) Ryota Tanaka et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

(2016) Christophe Massard et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Under-reporting of harm in clinical trials

(2016) Bostjan Seruga et al.   LANCET ONCOLOGY

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

(2016) Padmanee Sharma et al.   LANCET ONCOLOGY

Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes

(2016) Lisa Elliott et al.   Diabetes Therapy

Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes

(2016) Lisa Elliott et al.   Diabetes Therapy

A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors

(2015) T. W. Chen et al.   ANNALS OF ONCOLOGY

PD-1/PD-L1 inhibitors

(2015) Joel Sunshine et al.   CURRENT OPINION IN PHARMACOLOGY

A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G

(2015) Edgardo D. Carosella et al.   EUROPEAN UROLOGY

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

(2015) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

(2015) David F. McDermott et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunologic Checkpoints Blockade in Renal Cell, Prostate, and Urothelial Malignancies

(2015) Sergio Bracarda et al.   SEMINARS IN ONCOLOGY

Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center

(2015) Douglas B. Johnson et al.   Cancer Immunology Research

Safety of darunavir/ritonavir (DRV/r) in HIV-1-infected DRV/r-experienced and -naïve patients: analysis of data in the real-world setting in Italy

(2014) Andrea Antinori et al.   Journal of the International AIDS Society

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2013) David Moher   ANNALS OF INTERNAL MEDICINE

Effectiveness and safety of varenicline as an aid to smoking cessation: results of an inter-Asian observational study in real-world clinical practice

(2013) C. Wang et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Ipilimumab and Its Toxicities: A Multidisciplinary Approach

(2013) L. A. Fecher et al.   ONCOLOGIST

Evaluation of Adverse Events of Oral Antihyperglycaemic Monotherapy Experienced by a Geriatric Population in a Real-World Setting

(2009) Carl V Asche et al.   DRUGS & AGING